<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We defined whether <z:chebi fb="0" ids="27881">resveratrol</z:chebi> administration during the <z:hpo ids='HP_0011009'>acute</z:hpo> phase of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> reduces brain injury in mice </plain></SENT>
<SENT sid="1" pm="."><plain><z:mpath ids='MPATH_124'>Infarct</z:mpath> volumes were decreased significantly in both sexes with different doses of <z:chebi fb="0" ids="27881">resveratrol</z:chebi> (5mg/kg for males and 1mg/kg for females) administered 3h after <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Administration of <z:chebi fb="0" ids="27881">resveratrol</z:chebi> 6h after insult was also effective to decrease <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="27881">Resveratrol</z:chebi> suppressed expressions of IL-1β and TNF-α, microglial activation, and ROS production in the ischemic cortex </plain></SENT>
<SENT sid="4" pm="."><plain>The findings suggest that the suppression of <z:mp ids='MP_0001845'>inflammation</z:mp> is partly associated with the neuroprotective effects of <z:chebi fb="0" ids="27881">resveratrol</z:chebi>, and <z:chebi fb="0" ids="27881">resveratrol</z:chebi> can be developed as a therapeutic drug for <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
</text></document>